Latest News

Sep 12, 2019
Lytix Biopharma AS appoints Øystein Rekdal as the new CEO
Jun 20, 2019
Lytix Biopharma announces two recent publications on LTX-401, a second generation molecule developed for treatment of visceral tumors
Jun 20, 2019
Intratumoral treatment with LTX-315 causes regression of Desmoid Tumor- A case history
Jun 13, 2019
Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma joins Lytix as Company Strategic Advisors and in SAB